Immunocore (IMCR) Price Target Raised on Melanoma Trial Results
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowJefferies has raised its price target for Immunocore (IMCR), reflecting positive developments from recent melanoma trial results. This adjustment comes as the firm acknowledges the promising potential of Immunocore's therapies in oncology. A specific target price has not been disclosed in the article, but such revisions typically influence investor sentiment and stock performance. An increase in price target could attract more investment, impacting market activity and confidence in IMCR.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
